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Abstract
The purpose of this study was to investigate the association of visit-to-visit and 24-h BP variability 
with markers of endothelial injury and vascular function. We recruited 72 African Americans who 
were non-diabetic, non-smoking, and free of cardiovascular and renal disease. Office BP was 
measured at three visits and 24-h ambulatory BP monitoring was conducted to measure visit-to-
visit and 24-h BP variability, respectively. The 5-min time-course of brachial artery flow-mediated 
dilation and nitroglycerin-mediated dilation were assessed as measures of endothelial and smooth 
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muscle function. Fasted blood samples were analyzed for circulating endothelial microparticles. 
Significantly lower CD31+CD42− endothelial microparticles were found in participants with high 
visit-to-visit SBP variability or high 24-h DBP variability. Participants with high visit-to-visit 
DBP variability had significantly lower flow-mediated dilation and higher nitroglycerin-mediated 
dilation at multiple time-points. When analyzed as continuous variables, 24-h mean arterial 
pressure variability was inversely associated with CD62+ endothelial microparticles; visit-to-visit 
DBP variability was inversely associated with flow-mediated dilation normalized by smooth 
muscle function and was positively associated with nitroglycerin-mediated dilation; and 24-h DBP 
variability was positively associated with nitroglycerin-mediated dilation. All associations were 
independent of age, gender, BMI, and mean BP. In conclusion, in this cohort of African 
Americans visit-to-visit and 24-h BP variability were associated with measures of endothelial 
injury, endothelial function, and smooth muscle function. These results suggest that BP variability 
may influence the pathogenesis of cardiovascular disease, in part, through influences on vascular 
health.
Keywords
Blood pressure variability; endothelial function; endothelial microparticles; smooth muscle 
function; blood pressure; ambulatory blood pressure monitoring
INTRODUCTION
Evidence has accumulated to show that blood pressure variability (BPV) has a striking 
relationship with cardiovascular (CV) risk. Most notably, several general-population based 
studies have reported that measures of BPV within a 24-h period were independent 
predictors of CV events and all-cause mortality1–3. In addition to fluctuations in BP from 
reading-to-reading over a 24-h period, recent retrospective analyses of several randomized 
controlled trials and general-population based studies have shown that visit-to-visit 
variability in clinic BP is also a powerful predictor of CV events and all-cause mortality, 
independent of mean BP4–6.
Despite the mounting evidence, scant attention has been paid to the mechanisms by which 
high BPV may confer greater CV risk. Moreover, it is still not clear whether 24-h and visit-
to-visit BPV are two risk markers with different underlying causes and sequelae. Data from 
sinoaortic denervation (SAD) rats, the animal model of high BPV, suggests that the 
augmented mechanical stress placed on the vasculature as a result of increased BPV leads to 
the impairment and injury of the endothelium7–9. In accordance with these findings, we 
reported in a preliminary study that both 24-h and visit-to-visit BPV were associated with 
measures of endothelial- and smooth muscle-dependent vasodilation10. To the best of our 
knowledge, outside of this preliminary study, no previous clinical study has assessed the 
relationship between BPV and measures of endothelial health to elucidate the potential 
pathogenic effects of high BPV on the vasculature.
Endothelial dysfunction has conventionally been considered to be solely an impairment in 
endothelial-dependent vasodilation. However, this narrow focus has provided insight 
concerning only one aspect of endothelial cell function (i.e. their ability to induce arterial 
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vasodilation). In recent years, laboratory-based investigations have elucidated the processes 
underlying endothelial dysfunction and have identified endothelial microparticles (EMPs) as 
a novel direct biomarker of endothelial cell injury11. These endothelial-derived 
microparticles are submicroscopic fragments that are released from the plasma membrane of 
endothelial cells into circulation when endothelial cells are subjected to a number of stress 
conditions, including cell activation or cell apoptosis. Although long thought to be cellular 
debris, EMPs present in the blood are now widely considered to be a biological marker 
reflective of endothelial cell activation, degeneration, and apoptosis which have been shown 
to be elevated in a number of disease states11.
The purpose of this study was to extend upon our preliminary findings by comprehensively 
investigating the association of 24-h and visit-to-visit BPV with measures of endothelial and 
smooth muscle function through the assessment of the 5-min time-course vasodilatory 
response to reactive hyperemia and nitroglycerin, respectively, in a cohort of African 
Americans with a range of BP levels. In order to evaluate the relationship between BPV and 
endothelial health beyond just one aspect of endothelial cell function, as a secondary 
purpose we also investigated the association of 24-h and visit-to-visit BPV with circulating 
levels of endothelial microparticles (EMPs), a measure of endothelial cell injury.
METHODS
Participants
African Americans within the city of Philadelphia were recruited via newspaper 
advertisements. Participants were required to be 40–75 years old, sedentary, non-diabetic, 
non-smoking, have a clinic BP < 160/100 mmHg, and have no evidence or history of CV 
disease, hypercholesterolemia, or renal disease. Participants on medications that effect CV 
hemodynamics or who were on more than one antihypertensive medication were excluded 
from the study. Any participant receiving antihypertensive monotherapy (n = 17) was 
tapered off their medication. Medications were withdrawn for a 2-week washout period, at 
minimum, before testing. These inclusion criteria were used to create a more homogeneous 
group of middle- to older-age African Americans who were at low-to-moderate risk for CV 
disease, but who were free of substantial medical co-morbidities that could confound data 
interpretation. Each participant gave written informed consent. The protocol was approved 
by the Temple University Institutional Review Board.
Office BP Measurements
Office BP measurements were obtained in accordance with JNC-7 guidelines by laboratory 
personnel on three separate visits in a quiet, temperature controlled room12. Measurements 
were obtained in the morning, except under rare circumstances when participant scheduling 
issues required afternoon measurement. Seated BP measurements were measured using an 
aneroid sphygmomanometer (Omron, Model 11-675D, Vernon Hills, IL) after 5-min of 
quiet rest. An appropriate size cuff was determined by upper arm circumference. For each 
visit, BP measurements were performed in triplicate, 5-min apart, and the average of the 
three values was used as the representative BP for the visit. For primary analyses, the 
standard deviation was calculated to define visit-to-visit BPV. As a sensitivity analysis, 
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visit-to-visit BPV was also expressed as the coefficient of variation. The mean duration 
between visits 1 and 2 and visits 2 and 3 were 12 ± 2 days and 14 ± 3 days, respectively.
24-h ABPM
Participants underwent 24-h ABPM using a non-invasive portable BP monitor (SpaceLabs, 
Model 90219, Redmond, WA) as previously described13. Briefly, monitoring began in the 
morning of each participant’s typical day. A BP cuff was fitted to the participant’s non-
dominant arm with cuff size determined by upper arm circumference. BP measures were 
obtained at 30-min intervals during the day (6:00am–10:00pm) and 60-min intervals at night 
(10:00pm–6:00am). Only recordings of good technical quality (≥ 80% of valid 
measurements) were included in final analyses.
Mean values were calculated for 24-h SBP, DBP, mean arterial pressure (MAP), and heart 
rate (HR). Systolic BPV (SBPV), diastolic BPV (DBPV), MAP variability (MAPV), and 
HR variability (HRV) during the 24-h period were calculated using the average real 
variability (ARV) index13.The rationale for selecting the ARV index to calculate 24-h BPV 
is based on previous studies that have reported the ARV index to be a more reliable 
representation of time series variability than standard deviation or coefficient of 
variation14,15.
Forearm Hemodynamics Studies
Brachial artery diameter was measured in response to increased flow (flow-mediated 
vasodilation: FMD) and nitroglycerin (nitroglycerin-mediated vasodilation: NMD) as 
previously described16. Briefly, measurements were performed in the morning following an 
overnight fast in a quiet, temperature controlled room. All measurements of brachial artery 
diameter were taken after 10-min of lying in the supine position. Baseline images of the 
right brachial artery were first obtained. Reactive hyperemia was then induced by distal 
occlusion using a cuff inflated to suprasystolic pressure for 5-min on the right forearm. 
Brachial artery diameter was imaged immediately after and 1-min, 2-min, 3-min, 4-min, and 
5-min post-cuff release. After at least 15-min of rest, new baseline images were obtained 
and a 0.4mg nitroglycerin tablet was administered sublingually to assess smooth muscle-
dependent vasodilation. Images were recorded immediately after nitroglycerin 
administration and 1-min, 2-min, 3-min, 4-min, and 5-min post-nitroglycerin administration.
Data Analysis of Forearm Hemodynamics Studies
Arterial diameter was measured from the anterior to the posterior ‘m’ line at end-diastole, 
incident with the R-wave on the electrocardiogram. FMD and NMD were calculated as the 
relative (%) increase in diameter from baseline at each time-point. Peak % increases in 
diameter (%FMDpeak and %NMDpeak) and the 5-min time-course area under the curve 
(AUC; FMDAUC and NMDAUC) are reported as measures of endothelial and smooth muscle 
function. As an additional index of endothelial function, the FMD/NMD ratio was calculated 
using the peak % increase in diameter from FMD and NMD in order to correct for vascular 
smooth muscle function in each participant.
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Circulating EMPs were quantified using a method we have previously described17,18. 
Briefly, fasted blood samples were collected into EDTA tubes and were centrifuged at 2,000 
g for 20-min at 4°C immediately after collection. Plasma samples were then stored at −80°C 
until measurement. On the day of analysis, samples were thawed and centrifuged at 1500 g 
for 20-min at room temperature to obtain platelet poor plasma (PPP). The top two-thirds 
volume of PPP were then further centrifuged at 1500 g for 20-min at room temperature. A 
volume of 100 µl supernatant was then incubated with two different flurochrome-labeled 
antibody combinations to distinguish between EMP subpopulations: CD31-PE with CD42b-
FITC; and CD62E-PE alone. Samples were analyzed using BD LSRII flow cytometer (BD 
Biosciences, San Jose, CA) and BD FACSDIVA software (v 6.1.3; BD Biosciences). 
Forward scatter (FSC), side scatter (SSC) and each fluorescent channel were set in 
logarithmic scale. The upper limit gate on FSC/SSC plot was determined by 0.9 µm standard 
beads. Events within this gate were further analyzed on FITC/PE dot plot. CD31+ CD42− or 
CD62E+ events were defined as EMPs and were expressed as events per µl plasma.
Statistical Analyses
Of the 72 participants enrolled in the study, 8 participants did not have office BP measures 
on 3 separate visits and were excluded from all analyses of visit-to-visit BPV. Data are 
presented as means ± s.e. The univariate relationship of each clinical, demographic, and 
BPV variable with FMD, NMD, the FMD/NMD ratio, CD31+CD42− EMPs, and CD62+ 
EMPs were tested with Spearman’s rank correlation coefficient (rs). All variables 
significantly associated with a measure of vascular function in univariate analyses was then 
inserted separately into a multivariate regression model containing variables known to 
impact vascular function: age, gender, BMI, and mean BP (corresponding clinic or 24-h 
BP). In a sensitivity analysis, all univariate and multivariate models were repeated using 
visit-to-visit BPV expressed as the coefficient of variation. Each model was evaluated for 
multicollinearity among variables using the variance inflation factor. The variance inflation 
factor was < 5 for all models (range: 1.099–3.499).
For secondary analyses, participants were classified into groups according to their BPV. 
Any participant at or above the median for the BPV measure were classified as having high 
BPV, while any participant below the median were classified as having low BPV. 
Comparisons between groups were tested using the Mann-Whitney U test for continuous 
variables and Pearson’s χ2-test for dichotomous variables. Two-way repeated-measures 
ANOVA examining the main effects of time and BPV group on time-course FMD and 
NMD were run using Greenhouse-Geisser correction as appropriate. All FMD and NMD 
measures were log transformed for ANOVAs to account for non-normal distribution. 
Repeated-measures ANCOVA was conducted to evaluate group differences after adjustment 
for age, gender, BMI, and mean BP (corresponding clinic or 24-h BP). Post-hoc 
comparisons were conducted using the Mann-Whitney U test. Statistical analyses were 
performed using SPSS version 19.0 (SPSS, Chicago, IL).
Power analyses were conducted using the PS software (Power and Sample Size 
Calculations, version 3.0.12, Vanderbilt University, Nashville, TN). Power calculations 
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were based on the relationship of SBPV from ABPM with %FMD and, separately, the 
FMD/NMD ratio. The sample provided 80% power to detect an association between SBPV 
and %FMD with a slope of 0.37 or greater (α level 0.05, two-sided) and between SBPV and 
the FMD/NMD ratio of 0.03 or greater.
RESULTS
Study population characteristics
The study population consisted of 72 African Americans, including 12 males (16.7%) and 
60 females (83.3%). Mean age was 51.7 ± 0.7 years and mean BMI was 32.7 ± 0.6 kg/m2. 
The mean office SBP and DBP were 126.7 ± 1.5 mmHg and 81.1 ± 1.0 mmHg, respectively. 
Of the 72 participants, 24 (33.3%) were normotensive, 32 (44.4%) were pre-hypertensive, 
and 15 (20.8%) were hypertensive. For ABPM, mean 24-h SBP and DBP were 128.0 ± 0.5 
mmHg and 78.9 ± 1.1 mmHg, respectively. According to AHA criteria19, 27 participants 
(37.5%) had abnormal 24-h BP levels (24-h BP ≥ 135/85 mmHg).
Correlates of Endothelial-Dependent and Smooth Muscle-Dependent Vasodilation
The association of all clinical variables and BP parameters with any of the vascular 
measures in univariate and multivariate analyses are presented in Table 1 and Table 2, 
respectively. Age and HDL-C were negatively associated with %FMDpeak, however neither 
remained a significant predictor in multivariate analyses. For FMDAUC, LDL-C and 
triglycerides were positively associated, while HDL-C and visit-to-visit DBPV were 
negatively associated with FMDAUC. In multivariate analysis, only LDL-C and triglycerides 
remained significant predictors of FMDAUC. When endothelial function was assessed by 
normalizing FMD by smooth muscle function (FMD/NMD ratio), the only variables 
associated with the FMD/NMD ratio in univariate analyses were body weight and visit-to-
visit DBPV. In multivariate analyses, body weight and visit-to-visit DBPV remained 
significant predictors of the FMD/NMD ratio.
For measures of smooth muscle function, HDL-C, visit-to-visit SBPV, visit-to-visit DBPV, 
and 24-h DBPV all were significantly associated with %NMDpeak, while visit-to-visit 
SBPV, visit-to-visit DBPV, and 24-h DBPV were significantly associated with NMDAUC. 
After adjusting for covariates in multivariate regression analyses, visit-to-visit DBPV 
remained the only significant predictor of %NMDpeak, while visit-to-visit DBPV and 24-h 
DBPV remained the only significant predictors of NMDAUC.
Mean BP levels from office or 24-h ABPM were not significantly associated with any 
measure of endothelial or smooth muscle function. In sensitivity analyses, all results were 
similar when visit-to-visit BPV was expressed as the coefficient of variation instead of the 
standard deviation (data not shown).
When the relationships between brachial artery diameter and FMD and NMD derived 
variables were tested in univariate analyses, a significant positive association was found 
between FMDpeak and NMDpeak (rs = 0.41; p = 0.01), but not between FMDAUC and 
NMDAUC (rs = 0.11; p = 0.53). Brachial artery diameter was associated with NMDpeak (rs = 
−0.37; p = 0.006), but not with FMDpeak (rs = 0.11; p = 0.48). The FMD/NMD ratio was 
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significantly associated with FMDpeak (rs = 0.44; p = 0.005), NMDpeak (rs = −0.56; p = < 
0.001), FMDAUC (rs = 0.35; p = 0.03), and NMDAUC (rs = −0.61; p < 0.001).
Correlates of EMPs
In univariate analyses, body weight (rs = −0.32; p = 0.02) and 24-hour DBPV (rs = −0.33; p 
= 0.02) were negatively associated with CD31+CD42− EMPs. In multivariate analysis 
adjusting for age, gender, BMI, and mean BP, only body weight (B = −0.04 [95%CI: −0.08–
−0.01], partial correlation = −0.24; p = 0.01) remained a significant predictor of 
CD31+CD42− EMPs. For CD62+ EMPs, triglyceride levels (rs = 0.33; p = 0.01) was 
positively associated, while 24-h MAPV (rs = −0.29; p = 0.03) was negatively associated 
with CD62+EMPs. After adjustment for age, gender, BMI, and mean BP, triglyceride levels 
(B = 0.21 [95%CI: 0.04–0.37], partial correlation = 0.34; p = 0.02) and 24-h MAPV (B = 
−4.79 [95%CI: −8.78–−0.81], partial correlation = −0.33; p = 0.02) both remained 
significant predictors of CD62+ EMPs. Mean BP levels from office or 24-h ABPM were not 
significantly associated with either EMP marker.
Visit-to-Visit BPV Group Comparisons
Participants with higher visit-to-visit SBPV had significantly lower CD31+CD42− EMPs 
and a trend for lower CD62+ EMPs when compared to participants with lower visit-to-visit 
SBPV (Supplemental Table S1). There were no significant differences between the two 
groups for any measures of endothelial function. For smooth muscle function measures, 
participants with higher visit-to-visit SBPV had significantly higher %NMDpeak and 
NMDAUC. Repeated-measures ANOVA for the time-course NMD response showed a 
significant main effect of visit-to-visit SBPV group (F = 4.90; p = 0.03). The main effect of 
visit-to-visit SBPV group, however, was no longer significant (F = 2.89; p = 0.10) after 
adjusting for age, gender, BMI, and mean BP.
Participants with higher visit-to-visit DBPV showed a trend for lower CD62+ EMPs when 
compared to participants with lower visit-to-visit DBPV, however this difference did not 
reach statistical significance (Supplemental Table S2). For measures of endothelial function, 
the high visit-to-visit DBPV group had significantly lower FMDAUC and FMD/NMD ratio. 
Significant differences were also observed for measures of smooth muscle function as the 
high visit-to-visit DBPV group had significantly higher %NMDpeak and NMDAUC when 
compared to the low visit-to-visit DBPV group.
Figure 1 shows the time-course %change in brachial artery diameter across the 5-min after 
FMD for the visit-to-visit DBPV groups. Repeated-measures ANOVA showed a significant 
main effect of visit-to-visit DBPV group (F = 5.28; p = 0.03). Post-hoc comparisons showed 
that %FMD was significantly lower in the high visit-to-visit DBPV group immediately post-
cuff release (p = 0.03), and 2-min (p = 0.005), 3-min (p = 0.001), and 5-min (p = 0.02) post-
cuff release. The main effect of visit-to-visit DBPV group, however, was no longer 
significant (F = 3.06, p = 0.09) after adjusting for age, gender, BMI, and mean BP. Figure 2 
shows the time-course %change in brachial artery diameter across the 5-min after 
nitroglycerin administration for the visit-to-visit DBPV groups. Repeated-measures 
ANOVA showed a significant effect of visit-to-visit DBPV group (F = 13.55; p = 0.001). 
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The main effect of visit-to-visit DBPV group (F = 12.39; p = 0.001) remained significant 
after adjusting for age, gender, BMI, and mean BP. Post-hoc comparisons showed that 
%NMD was significantly higher in the high visit-to-visit DBPV group at 1-min (p = 0.002), 
2-min (p = 0.001), 3-min (p = 0.001), 4-min (p = 0.002), and 5-min (p = 0.001) post-
nitroglycerin administration.
24-h BPV Group Comparisons
There were no significant differences between participants with higher vs. lower 24-h SBPV 
for EMP levels, endothelial function measures, or smooth muscle function measures 
(Supplemental Table S3).
Participants with higher 24-h DBPV had lower CD31+CD42− and CD62+ EMPs when 
compared to participants with lower 24-h DBPV, however, these differences reached 
statistical significance only for CD31+CD42− EMPs (Supplemental Table S4). For 
measures of endothelial function, there were no differences between the two groups for any 
measure of endothelial function. For measures of smooth muscle function, trends were 
observed as participants with high 24-h DBPV had trends for higher %NMDpeak (p = 0.05) 
and NMDAUC (p = 0.06).
DISCUSSION
In this preliminary study, we investigated the relationship of two different measures of BPV 
with markers of endothelial injury, endothelial function, and smooth muscle function in a 
cohort of African Americans with a wide range of BP levels. Several important findings 
were observed. First, our results showed that African Americans with increased visit-to-visit 
DBPV had decreased endothelial function when assessed using the FMDAUC or the 
FMD/NMD ratio. Second, we found that higher visit-to-visit DBPV and 24-h DBPV were 
both associated with a greater vasodilatory response to NMD. Finally, our results 
unexpectedly showed that African Americans with increased BPV (visit-to-visit or 24-h) had 
lower circulating EMP levels.
In our previous preliminary study, we showed that increased visit-to-visit BPV was 
associated with diminished endothelial function assessed using the conventional approach to 
FMD calculation that expresses the brachial artery diameter using the arbitrary time point of 
60-sec post-cuff deflation10. However, it has been demonstrated that FMD calculated by this 
method (i.e. 60-sec diameter calculations) significantly underestimates true peak FMD20, 
thus our previous findings could have been confounded. In the present study, our finding 
that African Americans with high visit-to-visit DBPV have decreased endothelial function 
expressed as an AUC over a 5-min time course or as the normalized true peak in FMD, 
confirms and extends upon our preliminary study findings and provides some of the first 
clinical data that high BPV may be associated with impaired endothelial function. 
Nonetheless, as a result of the cross-sectional design of this study, it is difficult to ascertain 
whether high BPV precedes impaired endothelial function or vice versa.
It has been proposed by some that the FMD/NMD ratio is the best available marker of 
endothelial function because differences in the vascular smooth muscle response to nitric 
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oxide can be accounted for21,22. The most supportive data for the FMD/NMD ratio serving 
as the best available marker of endothelial function, comes from a study by Chan et al. who 
showed that the FMD/NMD ratio was a more powerful predictor of vascular events than 
FMD in coronary artery disease patients23. In the present study, the FMD/NMD ratio was 
negatively associated with measures of visit-to-visit DBPV; suggestive that endothelial-
specific vasodilatory mechanisms are impaired in African Americans with increased visit-to-
visit DBPV. Unfortunately, although the FMD/NMD ratio is used by some investigators, it 
is frequently not reported, thus its true prognostic value has not been clearly established. 
Therefore, although provocative, our findings may be tempered to some extent by a lack of 
studies investigating the prognostic importance of the FMD/NMD ratio. It should however 
be noted that there was a positive association found between %FMDpeak and %NMDpeak in 
the present study, which could suggest that smooth muscle function may be underlying 
and/or confounding the FMD response. Thus, normalizing FMD by NMD may have been 
warranted in our study.
In our previous preliminary study, we also reported that BPV was positively associated with 
%NMD at 4-min post-nitrogyclerin administration10, the conventional time point used to 
asses smooth muscle function. To further investigate this relationship, we analyzed NMD at 
multiple time-points and found that individuals with high visit-to-visit BPV had greater 
%NMD as early as 1-min post-nitroglycerin administration, which persisted up to 5-min 
post administration. Although purely speculative, we suspect that differences in vascular 
reactivity to vasoactive agents could be an underlying mechanism contributing to the greater 
CV risk in individuals with increased BPV, and itself could be a causative factor for higher 
BPV. Previous animal studies have reported differences in vascular reactivity to contractile 
and vasodilatory agonists between SAD rats and sham-operated rats which investigators 
attributed to differences in gap junction-mediated vascular smooth cell communication24. 
Based on these experimental findings, we hypothesize that a potential mechanism for the 
association between high BPV and a greater vasodilatory response to nitroglycerin observed 
in the present study could be the result of increased gap junction communication in the 
arteries of individual’s with high BPV. Additional clinical studies may be needed to further 
elucidate the relationship between BPV and vascular reactivity to other vasoactive agents 
(e.g. endothelin-1; angiotensin II); as such findings could provide insights as to the 
underlying mechanisms linking BPV to CV disease risk.
In recent years, EMPs have emerged as a novel biomarker that provides valuable 
information as to the biological status of the endothelium. Based on both experimental 
evidence that has demonstrated an active role for EMPs in the promotion and propagation of 
inflammation, coagulation, and thrombosis, as well previous clinical studies which have 
shown EMP levels to be elevated in a number of disease states11, we had hypothesized that 
individuals with higher BPV would have higher levels of EMPs. Contrary to our hypothesis, 
we observed that individuals with higher 24-h DBPV or visit-to-visit BPV had lower EMP 
levels. A potential explanation for these findings was recently introduced by Tushuizen et al. 
who contended that microparticles serve a critical role in cellular homeostasis and have 
protective properties in healthy and/or early disease states, and argued that impairment of 
the ability of the endothelium to release EMPs would result in the deterioration of 
endothelial cell integrity and/or viability25. According to this hypothesis, our finding that 
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higher BPV is associated with lower EMP levels may still be in agreement with our 
hypothesis that increased BPV elicits endothelial damage. Intuitively, lower levels of 
circulating EMPs could indicate that the ability of the endothelium to release EMPs has 
become impaired. Consequently, the integrity and viability of endothelial cells could be 
diminished in those participants with higher BPV. Coinciding with our findings and the 
hypothesis proposed by Tushuizen et al., it has been demonstrated that patients with 
subclinical atherosclerosis have higher circulating EMP levels when compared to patients 
with symptomatic atherosclerosis26,27. However, outside of these studies, little clinical 
evidence exists to substantiate the hypothesis that increased circulating EMP levels are 
indicative of a healthy endothelium.
It is also noteworthy to mention that although visit-to-visit and 24-h BPV have both been 
associated with clinical outcomes, seldom have they been investigated together in the same 
population. Here we report separate but similar relationships for measures of 24-h and visit-
to-visit BPV with measures of smooth muscle function, particularly for DBPV. Although 
they are certainly not interchangeable entities, our findings may provide early evidence that 
24-h BPV and visit-to-visit BPV could have some similar underlying causes and/or 
sequelae. Interestingly, in the only other study to date to compare visit-to-visit and 24-h 
BPV with clinical outcomes in the same population, it was observed that visit-to-visit BPV 
was a stronger predictor of vascular events in the ASCOT-BPLA trial than BPV derived 
from ABPM4; suggestive that visit-to-visit BPV may be more closely aligned with CV risk. 
Our study findings may be in agreement with this sentiment, as we showed that visit-to-visit 
BPV was more strongly associated with endothelial and smooth muscle function measures 
than 24-h BPV. However, the mechanisms for the stronger associations of visit-to-visit BPV 
with CV risk still remains to be elucidated.
Several limitations must be noted when interpreting our study findings. First, the 
reproducibility of visit-to-visit BPV when quantified using three visits may be low28. 
Second, it has been recommended that FMD should be normalized by dividing the 
percentage change of FMD by shear rate AUC in order to account for the heterogeneity of 
blood flow responses across subjects29. In our study, however, we did not normalize FMD 
by shear rate. Third, there are presently no standardized methods for the measurement of 
microparticles. Processing and analyzing techniques differ from investigator to investigator, 
thus comparisons across studies for EMPs should be done so cautiously. Fourth, only 
African Americans were included in the study. Therefore, our study findings are not 
generalizable to other race-ethnicities. Moreover, the sample population was predominately 
female, thus our findings also may have limited generalizability to male populations. Fifth, 
because of our recruitment procedures (e.g. advertisements), it is possible that our study 
could be confounded by a volunteer bias30. Finally, analyses were not adjusted for multiple 
testing, thus we cannot rule out the possibility of type I errors.
In conclusion, our findings showed that visit-to-visit and 24-h BPV were associated with 
measures of endothelial injury, endothelial function, and smooth muscle function. These 
early preliminary results may suggest that high BPV could influence the pathogenesis of CV 
disease, in part, through influences on vascular health. Additional research, however, will be 
needed to confirm these results, determine the clinical relevance of the FMD/NMD ratio, 
Diaz et al. Page 10













and resolve the conflicting hypotheses regarding the interpretation of circulating EMP 
levels.
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What is known about the topic
• Data from randomized controlled trials and general-population, propspetive 
studies have shown that both 24-hour blood pressure variablity and visit-to-visit 
variability in clinic blood pressure are associated with cardiovascular events and 
mortaility, independent of mean BP and other explanatory factors.
• Experimental studies in sinoaortic denervation rats, the animal model of blood 
pressure variability, have provided some evidence that high blood pressure 
variability could confer greater cardiovascular risk by elicting damage and 
injury to the endothelium.
What this study adds
• This cross-sectional study shows that visit-to-visit blood pressure variability, but 
not 24-hour blood pressure variability, is associated with endothelial-dependent 
vasodilation normalized for smooth muscle function in African Americans.
• Both 24-hour blood pressure varialbility and visit-to-visit blood pressure 
variability are associated with vascular smooth muscle-dependent vasodilation 
in African Americans.
• Visit-to-visit blood pressure variability is more closely with measure of vascular 
health/function than 24-hour blood pressure variability in African Americans.
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Time-course % change in brachial artery FMD in participants categorized as having low 
visit-to-visit diastolic blood pressure variability (solid line) or high visit-to-visit diastolic 
blood pressure variability (dotted line). * P < 0.05, † P < 0.01 between groups.
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Time-course % change in brachial artery nitroglycerin-mediated dilation in participants 
categorized as having low visit-to-visit diastolic blood pressure variability (solid line) or 
high visit-to-visit diastolic blood pressure variability (dotted line). † P < 0.01 between 
groups.
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